MOBIO's leadership continues to speak with one voice and together we have championed the life sciences and bio-technology for over a decade. Maintaining a sophisticated understanding of current dynamics, MOBIO serves as your trusted voice for bipartisan engagement and leadership.  MOBIO forges meaningful relationships between public and private sector leaders to: 

• Defend companies large and small

• Obtain and safeguard public investment

• Secure state funding for Missouri’s life science industry 

The strength of MOBIO's collective voice consistently delivers a compelling message to advance pro-science, pro-business environment. 

 SB 751 and HB 340 B Group Letter  -4/20/24

 HB 2763 B Support Letter  -3/7/24

 Medicaid Program; Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program [CMS-2434-P -10/19/2023

State Of Medical Technology Alliance -8/28/2023

Request for Action on Medical Research Matter; Nonhuman Primate Model Crisis 3/15/2023

Opposition to WTO TRIPS Waiver To Include Vaccines, and COVID-19 Therapeutics and Diagnostics 10/25/2022

Congressional Leadership Expressing Strong Concerns Over Senate Democrats’ Drug Pricing Proposals Letter 07/30/2022

Stand With Missouri Patients Against Government Interference 07/26/2022

Medicare and RX Access Network Missouri Urges Congress To Reauthorize The Prescription Drug User Fee Act (PDUFA)  05/26/2022

General Assembly Invests Heavily In MTC Update 05/13/2022

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Letter 05/09/2022

Mexico Measures on Agricultural Biotechnology Letter 11/17/21

Qualified Small Business Stock (QSBS) Letter 10/29/21

Multi-Cancer Early Detection Coverage Act 8/27/21

A Declaration from Members of the World’s Biotechnology Sector On Global Access to COVID Vaccines & Treatments and the Role of Intellectual Property   6/10/21

Republican Governors Association Summit  6/2/21

Missouri HR3 Statement of Opposition Letter 5/28/2021